On November 25, the 17th China Pharmaceutical Entrepreneurs, Scientists and Investors Conference 2025 (hereinafter referred to as the "Qisi Conference") opened in Beijing. With the theme of "Structural Inflection Point", the conference explored new opportunities in pharmaceutical innovation. At the opening ceremony, Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, delivered a keynote speech titled "Sino Biopharm: A New Decade, A New Starting Point". She pointed out that the inflection point for mergers and acquisitions (M&A) in China's pharmaceutical industry has arrived, and the future will see more precise M&A focused on cutting-edge technologies and more strategic integrations connecting to the global market. As a key player among China's innovative drug companies, Sino Biopharm is standing at a new starting point for a new decade, steadily advancing into the ranks of global innovative drug companies. 

M&A Inflection Point Arrives: China's Pharmaceutical Innovation Assets Become a Global Focus

Over the past five years, China's pharmaceutical industry has undergone a historic transformation, with a continuously improving innovation ecosystem, steadily progressing from a major pharmaceutical country to a powerhouse of pharmaceutical innovation. In terms of innovation outcomes, the number of innovative drugs approved for marketing in China has seen explosive growth, and the number of registered clinical trials has surpassed that of the United States for two consecutive years. 

At the market transaction level, the global appeal of Chinese pharmaceutical assets has significantly increased, making them a key target for multinational pharmaceutical companies facing patent cliffs. In the first half of 2025, the total transaction value of Chinese pharmaceutical companies reached US$66 billion, exceeding the total transaction volume for the entire year of 2024. 

Facing a golden cycle of industrial development, Sino Biopharm is driven by the dual wheels of strategic M&A and independent innovation, successfully transforming from a traditional pharmaceutical company into an innovative drug company. 

Strategic M&A is part of the company's core developmental DNA. Over the past 10 years, Sino Biopharm has collaborated with over 30 domestic and international enterprises. The acquisition of LaNova Medicines set a record for the largest domestic pharmaceutical M&A and was described by overseas media as "China's version of the Roche-Genentech acquisition". This acquisition completes the final piece of the puzzle in the neoplasm innovation of Sino Biopharm, achieving full-cycle coverage for the next generation of various genetic subtypes in lung cancer and gastrointestinal neoplasms such as gastric cancer and colorectal cancer. It also establishes a closed-loop R&D cycle from drug discovery and clinical development to registration and marketing. 

Driven by the dual wheels of M&A and independent innovation, the construction of technology platforms is also a key pillar of the company's core competitiveness. Over the past 10 years, Sino Biopharm has completed a critical innovation transformation, marking an important milestone in the company's development. In 2015, Sino Biopharm had only 2 innovative products, with innovative drug revenue accounting for just 10% of the total. Today, the number of innovative products has surged to 21, and the share of innovative drug revenue has risen to 50%, marking Sino Biopharm's official transformation into an innovation-driven enterprise. In the next three years, Sino Biopharm will enter a period of explosive growth in innovation outcomes, with the number of innovative products expected to exceed 30 by 2027, further optimizing the product structure and accelerating performance growth. 

Ms. Theresa Tse pointed out that with the rapid development of domestic innovative drugs, China's Biotech core technologies have become globally leading, and the time is now fully ripe for M&A of Chinese Biotech companies. In the past two years, MNCs including AstraZeneca and Novartis, and even Biopharma companies like BioNTech, have begun to acquire local Chinese assets. This is an opportunity for foreign companies, and even more so for local Chinese enterprises.

 
The M&A inflection point for pharmaceutical industry in China has arrived. In the future, we will witness more precise M&A focused on cutting-edge technologies and more strategic integrations connecting to the global market, which is an essential path for China to reach the next level.

 
Next-Generation I/O Cornerstone: Reshaping the Neoplasm Treatment Landscape

Looking ahead at the future technological development of the industry, Ms. Theresa Tse pointed out that new mechanisms, new targets, and new combinations are reshaping the next-generation immuno-oncology (I/O) treatment landscape. The clinical value and market potential of these blockbuster studies are profoundly influencing the global competitive landscape for neoplasm drugs, reshaping the hundred-billion-dollar market of the post-PD-1 era.
 

As an industry innovation pioneer, Sino Biopharm has developed a pipeline of multi-pathway, next-generation I/O therapies, including PD-1/CTLA-4 and PD-1/IL-2, covering the entire chain from immune regulation to tumor microenvironment (TME) modulation. The TME platform developed by Sino Biopharm can significantly reduce systemic toxicity by specifically identifying the tumor microenvironment. In addition, Sino Biopharm has also strategically focused on two next-generation technology platforms: siRNA and PROTAC. Among these, the siRNA platform focuses on liver, metabolic, and respiratory diseases, which explores new pathways for inhaled drug delivery. 

Disclaimer:
The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.